This article is more than 5 years old. Information may no longer be current.

SalutarisMD launches trial of brachytherapy treatment for wet AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A clinical trial of an ophthalmic brachytherapy device for neovascular age-related macular degeneration has been launched, according to a press release from Salutaris Medical Devices.

The trial will study the safety, surgeon ease of use and tolerability of the SMD-DA system with an anti-VEGF treatment regimen, the release said.

The multicenter, prospective, single-arm, open-label trial will enroll 20 patients who are within the first 18 months of receiving anti-VEGF treatment for wet AMD. One episcleral brachytherapy treatment will be delivered before 52 weeks of follow-up, during which time the patients will continue to receive anti-VEGF treatments.

“Our hope it to present a new option for the growing number of patients suffering from neovascular age-related macular degeneration, many of whom do not respond well to existing treatments,” Ryan Lohrenz, CEO of SalutarisMD, said in the release.